Akinsanya Karen 内部人交易：近期 SEC Form 4 交易
过去 18 个月，Akinsanya Karen（CIK 1797672）在 1 家公司共报告 8 笔 SEC Form 4 内部人交易（最近一笔 2026-09-21）。
| 日期 | 公司 | 身份 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 买入 | 31,599 | $137,140 |
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 卖出 | 10,000 | $280,000 |
| 2026-09-21 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 卖出 | 21,599 | $647,970 |
| 2026-03-06 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 卖出 | 1,366 | $17,621 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 买入 | 24,250 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 买入 | 6,077 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 买入 | 27,576 | $0 |
| 2026-03-03 | Schrodinger, Inc. (SDGR) | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 卖出 | 2,206 | $26,450 |
来源：SEC Form 4 申报文件 · 截至 2026-09-21